188 related articles for article (PubMed ID: 35083934)
21. Clinical Utility of Pharmacogene Panel-Based Testing in Patients Undergoing Percutaneous Coronary Intervention.
El Rouby N; Alrwisan A; Langaee T; Lipori G; Angiolillo DJ; Franchi F; Riva A; Elsey A; Johnson JA; Cavallari LH; Winterstein AG
Clin Transl Sci; 2020 May; 13(3):473-481. PubMed ID: 31758664
[TBL] [Abstract][Full Text] [Related]
22. Study design and rationale for Optimal aNtiplatelet pharmacotherapy guided by bedSIDE genetic or functional TESTing in elective percutaneous coronary intervention patients (ONSIDE TEST): a prospective, open-label, randomised parallel-group multicentre trial (NCT01930773).
Kołtowski Ł; Aradi D; Huczek Z; Tomaniak M; Sibbing D; Filipiak KJ; Kochman J; Balsam P; Opolski G
Kardiol Pol; 2016; 74(4):372-9. PubMed ID: 26365936
[TBL] [Abstract][Full Text] [Related]
23. Pharmacogenomics implementation in cardiovascular disease in a highly diverse population: initial findings and lessons learned from a pilot study in United Arab Emirates.
Al-Mahayri ZN; Khasawneh LQ; Alqasrawi MN; Altoum SM; Jamil G; Badawi S; Hamza D; George L; AlZaabi A; Ouda H; Al-Maskari F; AlKaabi J; Patrinos GP; Ali BR
Hum Genomics; 2022 Sep; 16(1):42. PubMed ID: 36154845
[TBL] [Abstract][Full Text] [Related]
24. Interventional cardiologists' attitudes towards pharmacogenetic testing and impact on antiplatelet prescribing decisions.
Hoffecker G; Kanter GP; Xu Y; Matthai W; Kolansky DM; Giri J; Tuteja S
Per Med; 2022 Jan; 19(1):41-49. PubMed ID: 34881641
[TBL] [Abstract][Full Text] [Related]
25. Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention.
Desai NR; Canestaro WJ; Kyrychenko P; Chaplin D; Martell LA; Brennan T; Matlin OS; Choudhry NK
Circ Cardiovasc Qual Outcomes; 2013 Nov; 6(6):694-9. PubMed ID: 24192573
[TBL] [Abstract][Full Text] [Related]
26. Clopidogrel Pharmacogenetics in Iranian Patients Undergoing Percutaneous Coronary Intervention.
Mahdieh N; Rabbani A; Firouzi A; Zahedmehr A; Hoseinimoghaddam M; Saedi S; Sanati H; Basiri H; Noohi F; Rabbani B; Maleki M
Cardiovasc Toxicol; 2018 Oct; 18(5):482-491. PubMed ID: 29777510
[TBL] [Abstract][Full Text] [Related]
27. Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
Zhong Z; Hou J; Zhang Q; Li B; Li C; Liu Z; Yang M; Zhong W; He X; Wu H; Zhong M; Zhao P
Eur J Clin Pharmacol; 2018 Apr; 74(4):423-431. PubMed ID: 29243114
[TBL] [Abstract][Full Text] [Related]
28. Ticagrelor Versus Clopidogrel in Patients with Two CYP2C19 Loss-of-Function Alleles Undergoing Percutaneous Coronary Intervention.
Xi Z; Zhou Y; Zhao Y; Liu X; Liang J; Chai M; Yu Y; Liu W
Cardiovasc Drugs Ther; 2020 Apr; 34(2):179-188. PubMed ID: 32140798
[TBL] [Abstract][Full Text] [Related]
29. Implementation and management outcomes of pharmacogenetic CYP2C19 testing for clopidogrel therapy in clinical practice.
Russmann S; Rahmany A; Niedrig D; Hatz KD; Ludin K; Burden AM; Englberger L; Backhaus R; Serra A; Béchir M
Eur J Clin Pharmacol; 2021 May; 77(5):709-716. PubMed ID: 33242107
[TBL] [Abstract][Full Text] [Related]
30. Bedside testing of CYP2C19 gene for treatment of patients with PCI with antiplatelet therapy.
Al-Rubaish AM; Al-Muhanna FA; Alshehri AM; Al-Mansori MA; Alali RA; Khalil RM; Al Faraidy KA; Cyrus C; Sulieman MM; Vatte C; Claassens DMF; Ten Berg JM; Asselbergs FW; Al-Ali AK
BMC Cardiovasc Disord; 2020 Jun; 20(1):268. PubMed ID: 32493215
[TBL] [Abstract][Full Text] [Related]
31. Identification of high-impact gene-drug pairs for pharmacogenetic testing in Alberta, Canada.
Fan M; Yarema MC; Box A; Hume S; Aitchison KJ; Bousman CA
Pharmacogenet Genomics; 2021 Feb; 31(2):29-39. PubMed ID: 32826605
[TBL] [Abstract][Full Text] [Related]
32. Are There Different Evidence Thresholds for Genomic Versus Clinical Precision Medicine? A Value of Information-Based Framework Applied to Antiplatelet Drug Therapy.
Guzauskas GF; Basu A; Carlson JJ; Veenstra DL
Value Health; 2019 Sep; 22(9):988-994. PubMed ID: 31511188
[TBL] [Abstract][Full Text] [Related]
33. Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients.
Ramsey LB; Ong HH; Schildcrout JS; Shi Y; Tang LA; Hicks JK; El Rouby N; Cavallari LH; Tuteja S; Aquilante CL; Beitelshees AL; Lemkin DL; Blake KV; Williams H; Cimino JJ; Davis BH; Limdi NA; Empey PE; Horvat CM; Kao DP; Lipori GP; Rosenman MB; Skaar TC; Teal E; Winterstein AG; Owusu Obeng A; Salyakina D; Gupta A; Gruber J; McCafferty-Fernandez J; Bishop JR; Rivers Z; Benner A; Tamraz B; Long-Boyle J; Peterson JF; Van Driest SL;
JAMA Netw Open; 2020 Dec; 3(12):e2029411. PubMed ID: 33315113
[TBL] [Abstract][Full Text] [Related]
34. Personalizing antiplatelet prescribing using genetics for patients undergoing percutaneous coronary intervention.
Cavallari LH
Expert Rev Cardiovasc Ther; 2017 Aug; 15(8):581-589. PubMed ID: 28699807
[TBL] [Abstract][Full Text] [Related]
35. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
Jiang M; You JH
Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429
[TBL] [Abstract][Full Text] [Related]
36. Feasibility and implementation of CYP2C19 genotyping in patients using antiplatelet therapy.
Bergmeijer TO; Vos GJ; Claassens DM; Janssen PW; Harms R; der Heide RV; Asselbergs FW; Ten Berg JM; Deneer VH
Pharmacogenomics; 2018 May; 19(7):621-628. PubMed ID: 29701129
[TBL] [Abstract][Full Text] [Related]
37. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.
Mostafa S; Kirkpatrick CMJ; Byron K; Sheffield L
J Neural Transm (Vienna); 2019 Jan; 126(1):5-18. PubMed ID: 30191366
[TBL] [Abstract][Full Text] [Related]
38. Diabetes and CYP2C19 Polymorphism Synergistically Impair the Antiplatelet Activity of Clopidogrel Compared With Ticagrelor in Percutaneous Coronary Intervention-treated Acute Coronary Syndrome Patients.
Mohareb MW; AbdElghany M; Zaki HF; El-Abhar HS
J Cardiovasc Pharmacol; 2020 Oct; 76(4):478-488. PubMed ID: 32675750
[TBL] [Abstract][Full Text] [Related]
39. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.
Pereira NL; Farkouh ME; So D; Lennon R; Geller N; Mathew V; Bell M; Bae JH; Jeong MH; Chavez I; Gordon P; Abbott JD; Cagin C; Baudhuin L; Fu YP; Goodman SG; Hasan A; Iturriaga E; Lerman A; Sidhu M; Tanguay JF; Wang L; Weinshilboum R; Welsh R; Rosenberg Y; Bailey K; Rihal C
JAMA; 2020 Aug; 324(8):761-771. PubMed ID: 32840598
[TBL] [Abstract][Full Text] [Related]
40. Prescription Patterns of Clopidogrel, Prasugrel, and Ticagrelor After Percutaneous Coronary Intervention With Stent Implantation (from the NCDR PINNACLE Registry).
Khalid U; Bandeali S; Jones PG; Virani SS; Hira R; Hamzeh I; Chan PS; Kleiman NS; Lakkis N; Alam M
Am J Cardiol; 2019 Dec; 124(12):1807-1812. PubMed ID: 31668345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
